503072-46-6

Basic information

• Product Name: 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester
• Synonyms: 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester;ethyl 2-Methanesulfonyl-pyrimidine-4-carboxylate;Ethyl 2-(Methylsulfonyl)pyriMidine-4-carboxylate;2-(methylsulfonyl)-4-Pyrimidinecarboxylic acid methyl ester
• CAS NO: 503072-46-6
• Molecular Formula: C₇H₈N₂O₄S
• Molecular Weight: 216.21
• Product Categories: Pyrimidine series
• Mol File: 503072-46-6.mol

Chemical Properties

• Boiling Point: 407.681°C at 760 mmHg
• Flash Point: 200.358°C
• Appearance: /
• Density: 1.338g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.511
• CAS DataBase Reference: 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester(503072-46-6)
• EPA Substance Registry System: 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester(503072-46-6)

Safety Data

• Hazardous Substances Data: 503072-46-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester is utilized as a reagent in organic synthesis for the production of various pharmaceuticals, including antidiabetic drugs. Its role as a building block in the synthesis of heterocyclic compounds further underscores its importance in this field.
Used in Medical Research:
2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester is also of interest in medical research due to its potential anti-inflammatory and antitumor properties, suggesting that it could be a valuable component in the development of new therapeutic agents.
It is crucial to handle and store 2-Methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester with care, as mishandling may lead to health and safety risks.

InChI:InChI=1/C8H10N2O4S/c1-3-14-7(11)6-4-5-9-8(10-6)15(2,12)13/h4-5H,3H2,1-2H3

Upstream product

• 1126-44-9 2-methylsulfanylpyrimidine-4-carboxylic acid 

Downstream Products

• 1224465-31-9 methyl 2-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)pyrimidine-4-carboxylate 
• 503072-50-2 2-phenoxy-pyrimidine-4-carboxylic acid 

Relevant articles and documents

6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to methods for treating diseases or disease states which are mediated or otherwise affected by the extracellular release of cytokines, said method comprising the step of administering to a human or higher mammal in need of treatment, one or more of the 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones of the present invention.

6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the for

6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R1 is substituted aryl; R4 is substituted or unsubstituted aryl or heteroaryl.

6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia

The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: 1wherein R comprises ethers or amines; R1 is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; each R2 unit is independently selected from the group consisting of: a) hydrogen; b) —(CH2)jO(CH2)nR8; c) —(CH2)jNR9aR9b; d) —(CH2)jCO2R10; e) —(CH2)jOCO2R10 f) —(CH2)jCON(R10)2; g) —(CH2)jOCON(R10)2; h) two R2 units can be taken together to form a carbonyl unit; i) and mixtures thereof; R8, R9a, R9b, and R10 are each independently hydrogen, C1-C4 alkyl, and mixtures thereof; R9a and R9b can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R10 units can be take together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5, n is an index from 0 to 5; Z is O, S, NR11, or NOR11; R11 is hydrogen or C1-C4 alkyl.

Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the form